600329.SHG Tianjin Zhongxin Pharmaceutical Group Corp Ltd
- Market cap
- CNY 32.7B
- P/E
- 37.0x
- P/B
- 5.32x
- ROE
- 19.7%
- Dividend yield
- 3.00%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600329.SHG undervalued?
Graham number600329.SHG trades 195.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Tianjin Zhongxin Pharmaceutical Group Corp Ltd fundamental analysis
No fundamental analysis for Tianjin Zhongxin Pharmaceutical Group Corp Ltd yet.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was …
Full company profileTianjin Zhongxin Pharmaceutical Group Corp Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 6.24B | 5.69B | 6.36B | 6.99B | 6.60B | 6.91B | 8.25B | 8.22B | 7.31B | 4.92B | 4.56B |
| Gross Profit | 2.02B | 2.20B | 2.62B | 2.92B | 2.58B | 2.75B | 3.26B | 3.59B | 3.50B | 3.64B | 3.47B |
| Operating Income | 436M | 526M | 642M | 759M | 785M | 867M | 980M | 1.10B | 2.57B | 971M | 1.44B |
| EBITDA | 331M | 404M | 519M | 625M | 661M | 701M | 786M | 948M | 893M | 2.61B | 1.42B |
| Net Income | 424M | 476M | 562M | 626M | 662M | 769M | 862M | 987M | 2.23B | 2.13B | 1.22B |
| EPS | 0.55 | 0.62 | 0.73 | 0.81 | 0.86 | 1.00 | 1.11 | 1.28 | 2.89 | 5.33 | 1.59 |
| Balance Sheet | |||||||||||
| Total Assets | 6.36B | 6.62B | 7.11B | 7.84B | 8.28B | 9.07B | 10.2B | 10.2B | 10.8B | 11.7B | 8.73B |
| Total Liabilities | 2.06B | 2.00B | 2.05B | 2.32B | 2.33B | 2.55B | 3.61B | 3.58B | 2.92B | 4.59B | 2.52B |
| Shareholders' Equity | 4.14B | 4.48B | 4.93B | 5.39B | 5.81B | 6.36B | 6.52B | 6.60B | 7.84B | 7.10B | 6.22B |
| Cash & Short-term Investments | 1.15B | 992M | 1.52B | 1.52B | 1.99B | 2.28B | 2.88B | 2.15B | 3.94B | 1.02B | 1.31B |
| Total Debt | 305M | 262M | 252M | 33.7M | 32.7M | 33.2M | 258M | 326M | 27.3M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 420M | -3.97M | 350M | 495M | 671M | 852M | 677M | 688M | 925M | 461M | - |
| Capital Expenditure | 116M | 114M | 176M | 206M | 189M | 157M | 108M | 141M | 118M | 119M | 105M |
| Free Cash Flow | 304M | -118M | 174M | 290M | 482M | 695M | 569M | 548M | 807M | 342M | 1.04B |
| Ratios | |||||||||||
| ROE | 10.2% | 10.6% | 11.4% | 11.6% | 11.4% | 12.1% | 13.2% | 14.9% | 28.4% | 30.0% | 19.7% |
| ROA | 6.7% | 7.2% | 7.9% | 8.0% | 8.0% | 8.5% | 8.5% | 9.6% | 20.7% | 18.2% | 14.0% |
| Net Profit Margin | 6.8% | 8.4% | 8.8% | 8.9% | 10.0% | 11.1% | 10.4% | 12.0% | 30.5% | 43.3% | 26.8% |
| Debt to Equity | 0.07x | 0.06x | 0.05x | 0.01x | 0.01x | 0.01x | 0.04x | 0.05x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd dividends
- Dividend yield
- 3.00%
- Forward dividend
- 4.79 CNY
- Payout ratio
- 46.0%
- Ex-dividend date
- Jul 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 981M | 2.45 | 46.0% |
| 2024 | CNY 1.01B | 1.31 | 45.3% |
| 2023 | CNY 859M | 1.11 | 87.1% |
| 2022 | CNY 387M | 0.50 | 44.9% |
| 2021 | CNY 232M | 0.30 | 30.2% |
| 2020 | CNY 232M | 0.30 | 35.0% |
| 2019 | CNY 169M | 0.22 | 27.0% |
| 2018 | CNY 165M | 0.21 | 29.3% |
| 2017 | CNY 127M | 0.17 | 26.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 2:1 on Jul 5, 2010.
Who owns Tianjin Zhongxin Pharmaceutical Group Corp Ltd
- Insiders 57.16%
- Institutions 2.09%
- Public & others 40.75%
- Shares outstanding 570M
- Free float 426M
Tianjin Zhongxin Pharmaceutical Group Corp Ltd company profile
- Company name
- Tianjin Zhongxin Pharmaceutical Group Corp Ltd
- Ticker
- 600329.SHG
- ISIN
- CNE000001808
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 27, 1997
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 3,890
- Fiscal year end
- December
- Address
- No. 17, Baidi Road, Tianjin, China, 300193
- Phone
- 86 22 2702 0892
- Website
- jydrt.com.cn
About Tianjin Zhongxin Pharmaceutical Group Corp Ltd
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited engages in the research, development, processing, manufacturing, and sale of traditional Chinese medicine in China. It provides pharmaceutical products for cardiovascular and cerebrovascular, skin wound repair, health preservation, respiratory, digestion, rheumatism and osteodynia, urological, gynecological and pediatric, ophthalmological, tumor, chronic, and other diseases, as well as tonic drugs. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. The company was founded in 1915 and is based in Tianjin, the People's Republic of China.
Tianjin Zhongxin Pharmaceutical Group Corp Ltd management
9- Ms. Lei WangChairman of the Board · born 1971
- Mr. Jian MaChief Financial Officer · born 1978
- Mr. Hong ZhouDeputy GM, Chief Engineer & Executive Director · born 1970
- Mr. Min GuoExecutive Director · born 1971
- Mr. Yu ZhangChief Manufacturing Officer · born 1973
- Mr. Mingjie ShangEmployee Director · born 1969
- Ms. Yan JiaoSecretary to the Board of Directors · born 1977
- Tang ChaoAccounting Supervisor
- Mr. Hong ChenExecutive Vice President · born 1971